Risedronic acid

From WikiProjectMed
Jump to navigation Jump to search
Risedronic acid
Risedronate.svg
Names
Trade namesActonel, Atelvia, Benet, others
  • (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid
Clinical data
Drug classBisphosphonate[1]
Main usesOsteoporosis, Paget's disease of bone[1]
Pregnancy
category
  • AU: B3
  • US: N (Not classified yet)
Routes of
use
By mouth
External links
AHFS/Drugs.comMonograph
Legal
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetics
Bioavailability0.63%
Protein binding~24%
MetabolismNone
Elimination half-life1.5 h
ExcretionKidney and fecal
Chemical and physical data
FormulaC7H11NO7P2
Molar mass283.112 g·mol−1
3D model (JSmol)
  • OC(Cc1cccnc1)(P(=O)(O)O)P(=O)(O)O
  • InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15) ☒N
  • Key:IIDJRNMFWXDHID-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Risedronic acid, often used as its salt risedronate sodium, is a bisphosphonate used to treat and prevent osteoporosis or to treat Paget's disease of bone.[1] It is taken by mouth.[1]

Common side effects include constipation, nausea, headache, and rash.[1] Other side effects may include esophageal inflammation, esophageal perforation, osteonecrosis of the jaw, low calcium, and muscle pain.[1] Use is not recommended in those with significant kidney problems.[2] It works by inhibiting the cells which break down bone.[1]

Risedronic acid was patented in 1984 and approved for medical use in 1998.[3] It is available as a generic medication.[4] In the United States it costs about 30 USD per month as of 2021.[4] In the United Kingdom it costs the NHS about £10 per month.[2]

Medical uses

Dosage

It may be taken as 5 mg a day, 35 mg a week, or 150 mg a month.[1]

Side effects

In common with other bisphosphonate drugs, risedronate appears to be associated with the rare side effect osteonecrosis of the jaw, often preceded by dental procedures inducing trauma to the bone.

Pharmacology

Relative potency[5]
Bisphosphonate Relative potency
Etidronate 1
Tiludronate 10
Pamidronate 100
Alendronate 100-500
Ibandronate 500-1000
Risedronate 1000
Zoledronate 5000

Society and culture

Brand names

It is produced and marketed by Warner Chilcott, Sanofi-Aventis, and in Japan by Takeda under the trade names Actonel, Atelvia, and Benet. It is also available in a preparation that includes a calcium carbonate supplement, as Actonel with Calcium.

Controversies

In January 2006 P&G and its marketing partner Sanofi-Aventis filed a Lanham Act false claims lawsuit against rival drugmakers Roche and GlaxoSmithKline claiming false advertising about Boniva.[6] The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. In a ruling on September 7, 2006 U.S. District Judge Paul A. Crotty rejected P&G's attempted injunction. P&G was criticized for attempting to "preserve its market share by denigrating Boniva". Judge Crotty wrote that "Roche was clearly entitled to respond with its own data, provided that the data was truthfully and accurately presented".[7]

In 2006, P&G faced controversy over its handling of clinical research involving risedronate (News Reports[8] and discussion).[9]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "Risedronate Monograph for Professionals". Drugs.com. Retrieved 19 July 2021.
  2. 2.0 2.1 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 770. ISBN 978-0-85711-369-6.CS1 maint: date format (link)
  3. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 523. ISBN 9783527607495.
  4. 4.0 4.1 "Risedronate Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 19 July 2021.
  5. Tripathi KD (30 September 2013). Essentials of medical pharmacology (Seventh ed.). New Delhi. ISBN 9789350259375. OCLC 868299888.
  6. "P&G Press statement". Uk.pg.com. Retrieved 2013-03-01.
  7. "Boniva advertising 'not misleading' says US judge". Pharma Times. 8 September 2006.
  8. "Actonel Case Media Reports". Scientific Misconduct Wiki. Archived from the original on 2 February 2009.
  9. "Scientific Misconduct Blog". Scientific-misconduct.blogspot.com. Retrieved 2013-03-01.

External links

Identifiers: